# AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Source: https://onco.cc/trials/nct05211570/  
OnCo record `nct05211570` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Venetoclax in acute myeloid leukaemia, run by AB Science, now recruiting.

## Summary

AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia is a phase 1/2 interventional study registered as NCT05211570 by AB Science, with 78 participants planned, started 2022-06-01 and due to reach its primary completion in 2026-08. Interventions recorded: AB8939 and Venetoclax.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05211570
- Phase: 1/2
- Setting: A Phase 1/2 Study to Assess the Safety, Pharmacokinetics, and Efficacy of Daily Intravenous AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Sponsor: AB Science
- Enrolled: 78

## Sources

- ClinicalTrials.gov NCT05211570: https://clinicaltrials.gov/study/NCT05211570

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- drugs: [Venetoclax](https://onco.cc/drugs/venetoclax/)
- companies: [AB Science](https://onco.cc/companies/ab-science/)

---
JSON: https://onco.cc/api/v1/entities/nct05211570.json